Lomitapide is under clinical development by Amryt Pharma and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Lomitapide’s likelihood of approval (LoA) and phase transition for Familial Chylomicronemia (Type I Hyperlipoproteinemia) took place on 31 Mar 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lomitapide Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Lomitapide overview

Lomitapide (Lojuxta/Juxtapid) belongs to cholesterol lowering agents class. It is formulated as hard gelatin capsules for oral route of administration. It is indicated as an adjunct to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C).

The drug candiate is under development for the treatment of homozygous familial hypercholesterolemia and familial chylomicronemia. It was under development for the treatment of dyslipidemia, hyperlipidemia, hypercholesterolemia.

Amryt Pharma overview

Amryt Pharma (Amryt) is a biopharmaceutical company that develops and commercializes novel treatments for patients with rare and orphan diseases. It has two marketed products including lomitapide for the treatment of adult HoFH and Metreleptin for the treatment of leptin deficiency. The company is also developing a portfolio of pipeline candidates, Oleogel-S10 and AP103 targeting multiple orphan diseases such as epidermolysis bullosa. The company offers its products in the US, Europe, the Middle East and Africa (EMEA). Amryt Pharma is headquartered in London, the UK.

Quick View Lomitapide LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Lomitapide
Administration Pathway
  • Oral
Therapeutic Areas
  • Metabolic Disorders
Key Developers
  • Sponsor Company: Amryt Pharma
  • Originator: Bristol-Myers Squibb
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.